Publications

Search our bibliography using the filters on the right-hand side.

Displaying 1 through 16 of 16 publications.

Gibble TH, Sweeney C, Wolin D, McSorley D, Wang J, Koushik AK, Moses RE, Dubinsky MC. Real-world experience and perspectives on the treatment of crohn's disease: results from a healthcare provider survey. Poster presented at the 2023 Advances in Inflammatory Bowel Diseases (AIBD) Annual Meeting; December 14, 2023. Orlando, FL. [abstract] Am J Gastroenterol. 2023 Dec; 118(12S):S19.

Charabaty A, Gibble TH, Moses R, Sweeney C, Wolin D, McSorley D, Wang J, Rodriguez M, Park B, Dubinsky M. Assessing bowel urgency in clinical practice: results from a healthcare professional survey. Poster presented at the AJG 2023 Annual Scientific Meeting; October 24, 2023. Vancouver, Canada. [abstract] Am J Gastroenterol. 2023 Oct; 118(10S):S894-5. doi: 10.14309/01.ajg.0000954312.41350.0a

Chang L, Ameen VZ, Dukes GE, McSorley DJ, Carter EG, Mayer EA. A dose-ranging, phase II study of the efficacy and safety of alosetron in men with diarrhea-predominant IBS. Am J Gastroenterol. 2004;99:1-9.

Northcutt AR, Perschy TL, Ameen VZ, Hamedani AG, McSorley DJ, Carter EG. Most bothersome symptoms in irritable bowel syndrome (IBS) patients. Am J Gastroenterol. 2004;99(10):842.

Northcutt AR, Perschy TL, Ameen VZ, Hamedani AG, McSorley DJ, Carter EG. Correlating global outcome measures in Irritable Bowel Syndrome (IBS). Am J Gastroenterol. 2004;99(10):843.

Wolfe SG, Chey WY, Washington MK, Harding J, Heath AT, McSorley DJ, Dukes GE, Hunt CM. Tolerability and safety of alosetron during long-term administration in female and male irritable bowel syndrome patients. Am J Gastroenterol. 2001 Mar;96(3):803-11.

Schwartz HI, Perschy TB, McSorley DJ, Sorrells SC. Twice-daily versus thrice-daily clarithromycin in combination with ranitidine bismuth citrate in the eradication of Helicobacter pylori. Am J Gastroenterol. 1999 Jun;4(2):121-7.

Mangel AW, Camilleri M, Chey WY, Hamm LR, Harding JP, Lawler C, McSorley DJ. Treatment of female IBS patients with alosetron, a potent and selective 5HT3-receptor antagonist. Am J Gastroenterol. 1999;116:G4505.

Mangel AW, Northcutt AR, Kong S, McSorley DJ. Validation of adequate relief as an endpoint in irritable bowel syndrome. Am J Gastroenterol. 1999;116:G4500.

Mangel AW, Camilleri M, Chey WY, Mayer EA, Northcutt AR, Heath AT, McSorley DJ. Alosetron, a 5-HT3 receptor antagonist, in the treatment of non-constipated female IBS patients. Am J Gastroenterol. 1999;94(9):2677.

Vakil N, McSorley DJ, Hahn BA. Clarithromycin-resistant helicobacter pylori in patients with duodenal ulcer in the United States. Am J Gastroenterol. 1998 Sep;93(9):1432-5.

Ciociola AA, McSorley DJ. Consistent criteria should be employed in calculating h. pylori (HP) eradication rates: application of different published study criteria to ranitidine bismuth citrate (RBC) clinical trial data. Am J Gastroenterol. 1996;91(9):1907.

Graham DY, Hirshowitz B, Ciociola AA, Sykes DL, McSorley DJ. Ranitidine bismuth citrate plus amoxicillin for the treatment of duodenal ulcer disease. Am J Gastroenterol. 1995;90(9):638.

Johnson JA, Euler AR, Northcutt AR, McSorley DJ. Ranitidine 300mg at bedtime is effective for gastric ulcers: a 12-week, multicenter, randomized, double-blind, placebo-controlled comparison. Am J Gastroenterol. 1993;88(7):1071-5.

Marshall B, Ciociola AA, McSorley DJ, Webb DD. Computerized phone-in symptom recording system correlates with patient recorded symptom diary card for patients with non-ulcer dyspepsia. Am J Gastroenterol. 1993;91(9):1992.

Euler AR, Johnson JA, Dawson D, Kleoudis C, McSorley DJ. A comparison of ranitidine 150mg and placebo administered at bedtime for maintenance of recurrent benign gastric ulcers. Am J Gastroenterol. 1992;87(9):1267.